PD-128,907 je lek koji se koristi u naučnim istraživanjima. On deluje kao potentan i selektivan agonistdopaminskihD2 i D3receptora.[1] On se koristi za studiranje uloge tih receptora u mozgu.[2][3] U životinjskim studijama je pokazano da redukuje toksičnost kokainskog predoziranja, te možda može da bude korstan u razvoju lekova kojima se tretiraju takva stanja kod ljudi.[4][5]
↑DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, Pugsley TA, Wise LD. Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. Journal of Medicinal Chemistry. 1990 Jan;33(1):445-50. PMID 1967318
↑Koeltzow TE, Xu M, Cooper DC, Hu XT, Tonegawa S, Wolf ME, White FJ. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. Journal of Neuroscience. 1998 Mar 15;18(6):2231-8. PMID 9482807
↑Chen G, Kittler JT, Moss SJ, Yan Z. Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. Journal of Neuroscience. 2006 Mar 1;26(9):2513-21. PMID 16510729
↑Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, Shannon HE, Gasior M. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]. Journal of Pharmacology and Experimental Therapeutics. 2004 Mar;308(3):957-64. PMID 14711932
↑Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors. Journal of Pharmacology and Experimental Therapeutics. 2008 Sep;326(3):930-8. PMID 18566292
